Clinical Trial Update: Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 open-label dose-escalation trial of NEOD001 in subjects with light chain (AL) amyloidosis completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyloidosis
• Light-chain Amyloidosis

Drugs mentioned

• NEOD001 (NEOD001)

Snippet

Sponsor: Prothena Biosciences Ltd. | Conditions: Primary Amyloidosis | Phase 1, Phase 2 | Status: COMPLETED